Ontvang nu dagelijks onze kooptips!
word abonnee
sluiten ✕
Terug naar discussie overzicht
In de investor presentation gaat men uit van topline,superieure resultaten? FINCH 1 and FINCH 3 topline expected in Q1 ‘19 Men had het toch gewoon over: 'FINCH 1 and FINCH 3 results expected in Q1 ‘19' kunnen hebben.
BLOO7 schreef op 11 maart 2019 10:24 :
In de investor presentation gaat men uit van topline,superieure resultaten?
FINCH 1 and FINCH 3
topline expected in Q1 ‘19
Men had het toch gewoon over:
'FINCH 1 and FINCH 3 results expected in Q1 ‘19'
kunnen hebben.
Nee. De term 'topline' is geen indicatie voor de efficacy/safety van de results. Zie bijvoorbeeld deze definitie:Top Line Data means with respect to a clinical study, a summary of demographic data, the data for the primary endpoint and a summary of safety data, which are based on an unblinded, locked database. All data will be collected in a 21 CFR 11 validated database with full audit trail. www.lawinsider.com/dictionary/top-lin...
dough ? @semodough 12m12 minutes ago $GLPG Galapagos: The company has started a new Phase II trial (NCT03864627) evaluating MOR106 administered concomitantly with topical Corticosteroids, in adult patients with Moderate to Severe Atopic Dermatitis.
New Phase 3 STELARA® (ustekinumab) Data Show Positive Results As Maintenance Therapy In Adults With Moderate To Severe Ulcerative Colitis seekingalpha.com/pr/17439322-new-phas...
Takeda's Entyvio beats Humira in head-to-head UC studyseekingalpha.com/news/3441395-takedas...
Lama Daila schreef op 11 maart 2019 17:33 :
Takeda's Entyvio beats Humira in head-to-head UC study
seekingalpha.com/news/3441395-takedas... Is dit een voor ons onbekende speler? Heeft iemand een idee of dit impact heeft op Filgotinib?
Takeda is een bekend bedrijf, maar Entyvio wordt per infuus toegediend en alleen al om die reden niet echt een concurrent. Voor filgotinib is voorlopig van belang hoe het zich verhoudt tot Humira en de overige JAK moleculen, met name de JAK-remmer van ABBV.
asti schreef op 11 maart 2019 20:05 :
Takeda is geen onbekend bedrijf. Entyvio wordt per infuus toegediend en alleen al om die reden niet echt een concurrent.
Voor filgotinib is voorlopig van belang hoe het zich verhoud tot Humira en de overige JAK moleculen, met name de JAK-remmer van ABBV.
dank je, ik schrok een beetje
Paniekvogel schreef op 11 maart 2019 20:07 :
[...] dank je, ik schrok een beetje
Je alias is niet voor niks Paniekvogel (sorry moest hem maken) ;-)
BLOO7 schreef op 11 maart 2019 10:24 :
In de investor presentation gaat men uit van topline,superieure resultaten?
FINCH 1 and FINCH 3
topline expected in Q1 ‘19
Men had het toch gewoon over:
'FINCH 1 and FINCH 3 results expected in Q1 ‘19'
kunnen hebben.
LOL, serieus?
Niet perse iets nieuws gehoord tijdens fire side chat, wel bevestiging dat readouts dit kwartaal gedaan zullen worden ('we'll have it soon'), alsook nogmaals de bevestiging van vertrouwen (filgotinib vormt 'backbone in inflammation therapeutic area'). Strekking van de chat mbt Filgotinib, uitspraken John McHutchison: - 1 of 4 top programs, in terms of advanced clinical stage developments; - drug is differentiated; waiting for 2 phase 3 readouts to allow us to put package together for RA - more importantly, most advanced JAK inhibitor in development Crohn's disease and (we believe) 2nd in UC (less aggressive market compared to RA, competitor wise); - waiting for total package (other two phase 3 readouts); JAK1 specificity, different rates of thrombo / infections, platelets, less HB reduction etc..; - let's see what the entire phase 3 package is, than we'll be able to move it forward; - backbone in inflammation therapeutic area upon which we will build (by adding other drugs/additional drugs for treatment of inflammatory bowel disease, RA and other). Tav 5 other diseases waar Filgotinib ook wordt ingezet (after careful analysis of commercial opportunities): we felt confident based on amount of large phase 2 data set by Galapagos (RA + Chrohn's disease), we continue to feel confident now. Let us allow the next phase 3 programs to read out so we will have a very large data set, which happens this quarter (Robin Washington op achtergrond; so we will have it soon).
seekingalpha.com/article/4248067-abbv... Transcript Abbvie op Cowen. Mooie update nav vragen over upadacitinib Steve Scala Okay. Questions? So, let's move to upadacitinib. So the approval of this agent should come in the second quarter. So, maybe you can… Mike Severino Second half. Steve Scala Second half second half, all right, I meant to say that. Tell us how the regulatory discussions are going here. And I appreciate the fact that it's more likely an FDA AdCom would be required here. So, maybe you can tell us your expectations there as well. Mike Severino Yes. Well, again, it starts with the data. And for upadacitinib, we have run a very broad and very comprehensive Phase 3 program that looks across a wide range of patient populations from very early patients who are naive to methotrexate to very advanced patients who've had multiple biologics. We have two structural studies where we showed a clear structural benefit which is important in this disease. We had a head-to-head against HUMIRA as well where we showed superiority across a wide range of endpoints. So, we have a very strong data package. We have a very strong benefit risk package as well to our eye. And we submitted that at the end of last year with approval in the second half of this year. Those discussions are obviously much earlier on than the risankizumab discussions. But I would characterize them as going entirely consistent with our expectations. With respect to an AdCom, it's a bit early to predict on upadacitinib given where we are in the regulatory review process in the U.S. But what I would say is that, advisory committees for NMEs for novel molecular entities in rheumatoid arthritis, it's common for the rheum division in the U.S. to have advisory committees. So, it wouldn't necessarily be surprising, if they chose to, but it's too early for us to know whether they will or they won't. Steve Scala I think some people in the investment community were rattled by the recent XELJANZ news about the CV findings at the above approved dose in RA, and because that to us was validation, or at least strong suggestion that it's now a class effect, it's not just baricitinib. Now that's just our conjecture. It doesn't mean its right. Tell us, how you view that? Mike Severino Well, I would return to our data. And so when you say the CV effects, I think you're referring to the thromboembolic events and PEs in particular were commented on in the press release from Pfizer and I think in some of the FDA communications. Those occurred at a dose higher than the approved dose in RA for that molecule and we're off to see how that plays through for XELJANZ. But I would return to our data set. We have generated a very robust data set across a wide range of patients, as I've said before. We studied two doses, a lower dose and a higher dose. The benefit risk of both doses was favorable certainly in our assessment. We didn't see any signal at either dose of risk for those sorts of events. And in fact, at the end of the Phase 3 program we put out rates, which across the board low dose high dose and comparators, showed no evidence of increased risk. And we've continued to monitor those patients to monitor our ongoing studies and our extensions. And nothing that, we've seen to-date changes our point of view around that. So I would really return to our data and the fact that our program, which was quite large, I mean, enrolled over 4,500 patients and studied them for studies that go up to a year and of course extensions that go beyond, are the best way to characterize our benefit risk and we feel very good about the profile that we've seen. Steve Scala I realize that this whole conversation is within the backdrop of a patient population, the RA patient population that has a background incidence of thromboembolic events to start. However, at least in our eyes, we looked at the 30 milligram dose as – versus the 15 and did think that there was what we would refer to as a signal. In fact, we put out a note on that. So I don't know, if you saw it or not. But just why does AbbVie think there is not a signal at 30? Mike Severino So, a couple of reasons. One is, when we look at the risk-adjusted and it's very hard – rather the exposure adjusted rates and it's very hard for an external party to do that, because you have event rates from clinical trials. You can have estimations of the exposure time, but you don't have the full exposure time. And the exposure time continues to accumulate on an ongoing basis. And certainly, well beyond at this point what was available when we released the data. When you look at those exposure-adjusted rates, they are not different from each other. So there's no evidence of the dose response. They're not different from comparators. In fact, they're numerically lower than some of the comparators. But given the uncertainty of the estimates, I would say they're not different from those comparators and they're not different from expectations of the baseline rates. And all of those features are important. Very early on in the Lilly experience the focus was solely on background rates and one can't look solely at background rates that's an important part of the equation, but one can't look solely at that. But when you look at the full picture, when you look at the fact that there is no dose relationship within our molecule, when you look at the rates compared to the comparators and there are a wide range of comparators methotrexate, adalimumab for most of the time some true placebo in our early study, we see a very, very consistent pattern, which to our eye shows no evidence of increased risk. Steve Scala I think strengthening AbbVie's position here is the fact that you will pursue the 30 milligram for other indications. So, what other indications indeed might the 30 milligrams be employed if you reveal that publicly? Mike Severino Yeah. Well, so in our first quarter call, we mentioned that, we wrote our rheumatoid arthritis file around the 15-milligram dose. And we did that based on our assessment of dose response for efficacy. I was talking about dose response for safety a second ago. But if you look at dose response for efficacy, we see in RA the overwhelming majority, if not all of the benefit being delivered by the 15-milligram dose. And in drug discovery and development, one always wants to select the lowest dose that delivers maximal efficacy. And when we reviewed the data in-house after completing the program in RA, we believe that that's a 15-milligram dose. And so that's the way we wrote that file. Now that maybe different in other indications. So for example, from the Phase 2 data in atopic dermatitis, there seems to be a dose response for efficacy between 15 milligrams and 30 milligrams. And so we will study both of those doses in that part of the program. In the inflammatory bowel disease program, so in Crohn's disease and ulcerative colitis particularly around induction, we will look at higher doses including the 30-milligram dose. So there are other components of the program where the exposure response for efficacy may be different where we might make a different dosing decision, but that will be driven by the data in those parts of the program. But from a benefit risk profile perspective, we view both 15 and the 30 as having a favorable benefit risk.
Geoff Meacham Let's switch gears to the filgotinib and the NASH portfolio and I'll have Jason do a few NASH questions. But just to the filgotinib program, you have a successful phase 3, you have another couple of studies coming out of them, and the priority should be an indicator of success there. But maybe, so from a development standpoint, how much of a strategic priority would you say filgotinib is? I mean, it's not liver disease. It's not - it's sort of an outlier, but it is - there are big markets and obviously, filgotinib could be differentiated in a very, very, very large market. So maybe just if you're sort of ranking your sort of pipeline and maybe your business priorities like where does that one fit in? John McHutchison We started inflammation and really got going on this a number of years ago and then the filgotinib opportunity presented itself. So, it's one of the four top programs right now in terms of advanced clinical stage development. It's the HIV programs, the NASH programs, the filgotinib programs and some other things and of course cell therapy. So it's one of our four biggest most advanced programs. Look, the drug is differentiated. Let me - I have two more phase, we have two more phase 3 trials that need to read out that'll allow us to put our package together for rheumatoid arthritis. More importantly, it's the most advanced JAK inhibitor in development for Crohn's disease and I believe - we believe will be second in ulcerative colitis. They're in less competitive markets or not as aggressively competitive as rheumatoid arthritis and this differentiating factor is important. This JAK1 specificity, different rates of thromboembolism infection, platelets, anemia, hemoglobin, preventing less hemoglobin reduction, et cetera, let's see what the entire phase 3 package is and then we'll be able to move it forward. It's also the backbone in our inflammation therapeutic area upon which we will build by adding other drugs or additional drugs for the treatment of inflammatory bowel disease, rheumatoid arthritis and other diseases. Geoff Meacham When you look across the universe of indications that other JAK inhibitors are going after, atopic derma is one, is there - do we have another wave of phase 3s with filgotinib or do you feel like that's a combination approach that you just mentioned with other assets? John McHutchison So, we have, it's a great question. We have five other diseases, we avoided the skin actually and didn't go down - we thought about atopic dermatitis, but we have uveitis, Sjögren's disease, ankylosing spondylitis, psoriatic arthritis, where we've announced that we will start a phase 3 program and lupus, particularly skin lupus and other types of Lupus. So they are the indications that we thought we should explore in proof of concept trials in phase 2. This was done after a careful analysis of the commercial opportunities and the necessity and need in those diseases. Geoff Meacham Obviously, if you're worried about the safety from the ongoing, the study, you wouldn't have started these phase 3s. I mean, should we read into that and I'm saying with respect to the filing? John McHutchison We've been bullish, we started those phase 2 trials a while ago before we had any safety data from phase 3. But we felt confident in the - when we started the relationship with Galapagos, the amount of phase 2 data they had in rheumatoid arthritis and in Crohn's disease from the Fitzroy study was a large data set for any company with the JAK inhibitor in phase 2. So we felt confident then, we continue to feel confident now. Let me - let us allow the next phase 2, phase 3 programs to read out, but they will have a very large data set which happens this quarter.
ik heb bovenstaande even door vertaal gehaald leest wat makkelijker. Laten we schakelen naar de filgotinib en de NASH-portfolio en ik zal Jason een paar NASH-vragen stellen. Maar alleen voor het filgotinib-programma, heb je een succesvolle fase 3, je hebt nog een paar studies die eruit komen en de prioriteit moet een indicator zijn voor succes daar. Maar misschien, vanuit ontwikkelingsoogpunt, hoeveel van een strategische prioriteit zou je zeggen, filgotinib is? Ik bedoel, het is geen leverziekte. Het is niet - het is een soort uitbijter, maar het is - er zijn grote markten en uiteraard kan filgotinib worden gedifferentieerd in een zeer, zeer, zeer grote markt. Dus misschien net als u een soort van rangschikking van uw soort van pijplijn en misschien uw zakelijke prioriteiten, zoals waar past die in past? John McHutchison We begonnen met een ontsteking en kregen dit een aantal jaren geleden echt onder handen en toen presenteerde zich de filgotinib-mogelijkheid. Het is dus een van de vier beste programma's op dit moment in termen van geavanceerde klinische ontwikkelingsfase. Het zijn de HIV-programma's, de NASH-programma's, de filgotinib-programma's en enkele andere dingen en natuurlijk celtherapie. Het is dus een van onze vier grootste en meest geavanceerde programma's. Kijk, het medicijn is gedifferentieerd. Laat me - ik heb nog twee fasen, we hebben nog twee fase 3-onderzoeken die moeten worden uitgelezen, zodat we ons pakket samen kunnen stellen voor reumatoïde artritis. Wat nog belangrijker is, het is de meest geavanceerde JAK-remmer die in ontwikkeling is voor de ziekte van Crohn en ik geloof - we geloven dat dit de tweede zal zijn in colitis ulcerosa. Ze zijn in minder competitieve markten of niet zo agressief als reumatoïde artritis en deze onderscheidende factor is belangrijk. Deze JAK1-specificiteit, verschillende percentages van trombo-embolie-infectie, bloedplaatjes, bloedarmoede, hemoglobine, het voorkomen van minder hemoglobineductie, enzovoort, laten we eens kijken wat het hele fase 3-pakket is en dan kunnen we het voorwaarts verplaatsen. Het is ook de ruggengraat in ons therapeutisch gebied voor onsteking waarop we zullen bouwen door andere geneesmiddelen of aanvullende geneesmiddelen toe te voegen voor de behandeling van inflammatoire darmaandoeningen, reumatoïde artritis en andere ziekten. Geoff Meacham Wanneer je kijkt naar het universum van indicaties waar andere JAK-remmers naar op zoek zijn, is atopische derma één, is er dan - hebben we nog een golf fase 3s met filgotinib of heb je het gevoel dat dit een combinatiebenadering is die je zojuist hebt genoemd met andere activa? ? John McHutchison Dus, we hebben het, het is een geweldige vraag. We hebben vijf andere ziekten, we hebben de huid eigenlijk vermeden en zijn niet naar beneden gegaan - we dachten aan atopische dermatitis, maar we hebben uveïtis, de ziekte van Sjögren, spondylitis ankylopoetica, arthritis psoriatica, waarbij we hebben aangekondigd dat we een fase 3 zullen starten programma en lupus, met name huidlupus en andere soorten lupus. Het zijn dus de indicaties die we dachten dat we in fase 2 zouden moeten onderzoeken als bewijs van conceptproeven. Dit gebeurde na een zorgvuldige analyse van de commerciële kansen en de noodzaak en noodzaak van die ziekten. Geoff Meacham Het is duidelijk dat als je je zorgen maakt over de veiligheid van de lopende, de studie, je deze fase 3s niet zou zijn begonnen. Ik bedoel, moeten we dat lezen en wat ik zeg met betrekking tot de indiening? John McHutchison We zijn optimistisch begonnen, we zijn die fase 2-proeven al een tijdje geleden begonnen voordat we veiligheidsgegevens uit fase 3 hadden. Maar we hadden vertrouwen in de - toen we de relatie met Galapagos begonnen, de hoeveelheid fase 2-gegevens die ze hadden in reumatoïde patiënten. artritis en de ziekte van Crohn uit de Fitzroy-studie was een grote dataset voor elk bedrijf met de JAK-remmer in fase 2. Dus we voelden ons toen zelfverzekerd, we blijven ons nu zeker voelen. Laat me - laten we de volgende fase 2, fase 3-programma's uit te lezen, maar ze zullen een zeer grote dataset hebben die dit kwartaal plaatsvindt.
Geoff Meacham And along those lines, I know we'll hear you know from Dan O'Day when he complete the sort of listening tour, then kind of gives his perspective, but I just want to get kind of Gilead as of now, is kind of the BD like M&A kind of approach. Because last year you've done some smaller deals or kind of bolt on to your existing assets and particularly the cell therapy, is that something going forward that you think is a implementable strategy for the balance of the year? Robin Washington Yeah, I think Geoff, so it's been two weeks for Dan. He's highly engaged, he spent a significant amount of time already with the BD team. And as we said all along, we've continued to be very aggressively focused on what external assets make sense to add to our portfolio and we continue to be. So stay tuned, but I would say he is integrated perfectly into the process for getting them up to speed, but it hasn't necessarily slowed us down in any way, shape or form. We remain committed and focused to look for those right next set of assets.
Wall Street Trader schreef op 13 maart 2019 11:40 :
This trial is ongoing. It must report results 6 days, 13 hours from now.
Full entry on ClinicalTrials.gov
NCT02873936 A Randomized, Double-blind, Placebo-controlled, Multicenter, Phase 3 Study to Assess the Efficacy and Safety of Filgotinib Administered for 24 Weeks in Combination With Conventional Synthetic Disease-modifying Anti-rheumatic Drug(s) (csDMARDs) to Subjects With Moderately to Severely Active Rheumatoid Arthritis Who Have an Inadequate Response to Biologic DMARD(s) Treatment
Required reporting date March 20, 2019, midnight fdaaa.trialstracker.net/trial/NCT0287... Dit betrof Finch 2 ....
@ Up up and awayYou are right. Everybody can ignore my last post. I don't know how to delete the message on this forum board.
Het was even stil met nieuwe vacatures, maar nu ook weer een nieuwe aangaande Toledowww.glpg.com/careers-job/job-info/med...
Van een ander forum. Kritische blik van Pate. “En ga je er dan ook van uit dat de FDA onderscheid gaat maken tussen filgotinib en zijn voorgangers? Ik hou er na de gebeurtenissen van de voorbije maanden ernstig rekening mee dat de FDA alle (dus ook filgotinib) JAK-inhibitoren over dezelfde kam zal scheren. Op basis van onderstaande elementen kan ik me perfect voorstellen dat de FDA op veilig zal spelen. 1) AbbVie is momenteel de FDA aan het vertellen dat upadacitinib een selectieve JAK1 inhibitor is. En zoals geweten kwamen er bij upadacitinib nogal wat VTEs (PE en/of DVT) voor. 2) Toen Xeljanz (tofacitinib) in de US werd goedgekeurd werden VTEs nog niet in verband gebracht met JAK-inhibitie. Het is maar na het optreden van VTEs bij baricitinib dat de FDA gealarmeerd werd. Naar aanleiding van de gebeurtenissen met baricitinib werden ook de VTEs opgelijst die optraden tijdens fase II en fase III studies met Xeljanz . Voor een overzicht zie o.a. acrabstracts.org/abstract/incid ... -programs/ Het mag duidelijk zijn dat Xeljanz hier redelijk goed scoorde. 3) Xeljanz zelf wordt eigenlijk maar echt in verband gebracht met VTEs na een tussentijdse evaluatie van een post-marketing studie bij patiënten die een wat hoger risico op deze aandoeningen hebben. Bij dergelijke patiënten werd filgotinib nog niet getest. Hoe kunnen Gilead en Galapagos de FDA overtuigen dat filgotinib 100% veilig is? Het verhaal van de erg selectieve JAK1 inhibitie ligt allicht wat moeilijker na de passage van upadacitinib bij de FDA. Tijdens FINCH 2 was er een patiënt met een bloedklonter in de buurt van het oog. Was dat levensbedreigend zoals PE en/of DVT? Neen, maar als de FDA met een vergrootglas naar thrombose-verschijnselen gaat kijken is het toch ook geen cadeau. En in fase II studies waren er volgens mij ook al 3 VTEs opgetreden bij patiënten die filgotinib namen. Zelfs zonder nieuwe VTEs in FINCH 1 en FINCH3 doet filgotinib dus niet echt veel beter dan Xeljanz. Bijkomend aandachtspunt is dat al deze VTEs optraden bij 200 mg filgotinib. Ook al geen cadeau. Ik acht het zeer goed mogelijk dat de FDA op veilig gaat spelen en dat de labels van zowel upadacitinib als filgotinib serieuze waarschuwingen gaan bevatten voor bloedklonters totdat post-marketing studies bij risico-patiënten het tegendeel bewezen hebben. En in post-marketing studies kan filgotinib eventueel wel zijn beter veiligheidsprofiel bewijzen maar vooraleer die gegevens er zijn zijn we heel wat jaren verder. PS Het kan toeval zijn maar sedert enkele weken zijn mijn Galapagos aandelen uitgeleend aan shorters.”
Aantal posts per pagina:
20
50
100
Direct naar Forum
-- Selecteer een forum --
Koffiekamer
Belastingzaken
Beleggingsfondsen
Beursspel
BioPharma
Daytraders
Garantieproducten
Opties
Technische Analyse
Technische Analyse Software
Vastgoed
Warrants
10 van Tak
4Energy Invest
Aalberts
AB InBev
Abionyx Pharma
Ablynx
ABN AMRO
ABO-Group
Acacia Pharma
Accell Group
Accentis
Accsys Technologies
ACCSYS TECHNOLOGIES PLC
Ackermans & van Haaren
ADMA Biologics
Adomos
AdUX
Adyen
Aedifica
Aegon
AFC Ajax
Affimed NV
ageas
Agfa-Gevaert
Ahold
Air France - KLM
Airspray
Akka Technologies
AkzoNobel
Alfen
Allfunds Group
Allfunds Group
Almunda Professionals (vh Novisource)
Alpha Pro Tech
Alphabet Inc.
Altice
Alumexx ((Voorheen Phelix (voorheen Inverko))
AM
Amarin Corporation
Amerikaanse aandelen
AMG
AMS
Amsterdam Commodities
AMT Holding
Anavex Life Sciences Corp
Antonov
Aperam
Apollo Alternative Assets
Apple
Arcadis
Arcelor Mittal
Archos
Arcona Property Fund
arGEN-X
Aroundtown SA
Arrowhead Research
Ascencio
ASIT biotech
ASMI
ASML
ASR Nederland
ATAI Life Sciences
Atenor Group
Athlon Group
Atrium European Real Estate
Auplata
Avantium
Axsome Therapeutics
Azelis Group
Azerion
B&S Group
Baan
Ballast Nedam
BALTA GROUP N.V.
BAM Groep
Banco de Sabadell
Banimmo A
Barco
Barrick Gold
BASF SE
Basic-Fit
Basilix
Batenburg Beheer
BE Semiconductor
Beaulieulaan
Befimmo
Bekaert
Belgische aandelen
Beluga
Beter Bed
Bever
Binck
Biocartis
Biophytis
Biosynex
Biotalys
Bitcoin en andere cryptocurrencies
bluebird bio
Blydenstijn-Willink
BMW
BNP Paribas S.A.
Boeing Company
Bols (Lucas Bols N.V.)
Bone Therapeutics
Borr Drilling
Boskalis
BP PLC
bpost
Brand Funding
Brederode
Brill
Bristol-Myers Squibb
Brunel
C/Tac
Campine
Canadese aandelen
Care Property Invest
Carmila
Carrefour
Cate, ten
CECONOMY
Celyad
CFD's
CFE
CGG
Chinese aandelen
Cibox Interactive
Citygroup
Claranova
CM.com
Co.Br.Ha.
Coca-Cola European Partners
Cofinimmo
Cognosec
Colruyt
Commerzbank
Compagnie des Alpes
Compagnie du Bois Sauvage
Connect Group
Continental AG
Corbion
Core Labs
Corporate Express
Corus
Crescent (voorheen Option)
Crown van Gelder
Crucell
CTP
Curetis
CV-meter
CVC Capital Partners
Cyber Security 1 AB
Cybergun
D'Ieteren
D.E Master Blenders 1753
Deceuninck
Delta Lloyd
DEME
Deutsche Cannabis
DEUTSCHE POST AG
Dexia
DGB Group
DIA
Diegem Kennedy
Distri-Land Certificate
DNC
Dockwise
DPA Flex Group
Draka Holding
DSC2
DSM
Duitse aandelen
Dutch Star Companies ONE
Duurzaam Beleggen
DVRG
Ease2pay
Ebusco
Eckert-Ziegler
Econocom Group
Econosto
Edelmetalen
Ekopak
Elastic N.V.
Elia
Endemol
Energie
Energiekontor
Engie
Envipco
Erasmus Beursspel
Eriks
Esperite (voorheen Cryo Save)
EUR/USD
Eurobio
Eurocastle
Eurocommercial Properties
Euronav
Euronext
Euronext
Euronext.liffe Optiecompetitie
Europcar Mobility Group
Europlasma
EVC
EVS Broadcast Equipment
Exact
Exmar
Exor
Facebook
Fagron
Fastned
Fingerprint Cards AB
First Solar Inc
FlatexDeGiro
Floridienne
Flow Traders
Fluxys Belgium D
FNG (voorheen DICO International)
Fondsmanager Gezocht
ForFarmers
Fountain
Frans Maas
Franse aandelen
FuelCell Energy
Fugro
Futures
FX, Forex, foreign exchange market, valutamarkt
Galapagos
Gamma
Gaussin
GBL
Gemalto
General Electric
Genfit
Genmab
GeoJunxion
Getronics
Gilead Sciences
Gimv
Global Graphics
Goud
GrandVision
Great Panther Mining
Greenyard
Grolsch
Grondstoffen
Grontmij
Guru
Hagemeyer
HAL
Hamon Groep
Hedge funds: Haaien of helden?
Heijmans
Heineken
Hello Fresh
HES Beheer
Hitt
Holland Colours
Homburg Invest
Home Invest Belgium
Hoop Effektenbank, v.d.
Hunter Douglas
Hydratec Industries (v/h Nyloplast)
HyGear (NPEX effectenbeurs)
HYLORIS
Hypotheken
IBA
ICT Automatisering
Iep Invest (voorheen Punch International)
Ierse aandelen
IEX Group
IEX.nl Sparen
IMCD
Immo Moury
Immobel
Imtech
ING Groep
Innoconcepts
InPost
Insmed Incorporated (INSM)
IntegraGen
Intel
Intertrust
Intervest Offices & Warehouses
Intrasense
InVivo Therapeutics Holdings Corp (NVIV)
Isotis
JDE PEET'S
Jensen-Group
Jetix Europe
Johnson & Johnson
Just Eat Takeaway
Kardan
Kas Bank
KBC Ancora
KBC Groep
Kendrion
Keyware Technologies
Kiadis Pharma
Kinepolis Group
KKO International
Klépierre
KPN
KPNQwest
KUKA AG
La Jolla Pharmaceutical
Lavide Holding (voorheen Qurius)
LBC
LBI International
Leasinvest
Logica
Lotus Bakeries
Macintosh Retail Group
Majorel
Marel
Mastrad
Materialise NV
McGregor
MDxHealth
Mediq
Melexis
Merus Labs International
Merus NV
Microsoft
Miko
Mithra Pharmaceuticals
Montea
Moolen, van der
Mopoli
Morefield Group
Mota-Engil Africa
MotorK
Moury Construct
MTY Holdings (voorheen Alanheri)
Nationale Bank van België
Nationale Nederlanden
NBZ
Nedap
Nedfield
Nedschroef
Nedsense Enterpr
Nel ASA
Neoen SA
Neopost
Neovacs
NEPI Rockcastle
Netflix
New Sources Energy
Neways Electronics
NewTree
NexTech AR Solutions
NIBC
Nieuwe Steen Investments
Nintendo
Nokia
Nokia OYJ
Nokia Oyj
Novacyt
NOVO-NORDISK AS
NPEX
NR21
Numico
Nutreco
Nvidia
NWE Nederlandse AM Hypotheek Bank
NX Filtration
NXP Semiconductors NV
Nyrstar
Nyxoah
Océ
OCI
Octoplus
Oil States International
Onconova Therapeutics
Ontex
Onward Medical
Onxeo SA
OpenTV
OpGen
Opinies - Tilburg Trading Club
Opportunty Investment Management
Orange Belgium
Oranjewoud
Ordina Beheer
Oud ForFarmers
Oxurion (vh ThromboGenics)
P&O Nedlloyd
PAVmed
Payton Planar Magnetics
Perpetuals, Steepeners
Pershing Square Holdings Ltd
Personalized Nursing Services
Pfizer
Pharco
Pharming
Pharnext
Philips
Picanol
Pieris Pharmaceuticals
Plug Power
Politiek
Porceleyne Fles
Portugese aandelen
PostNL
Priority Telecom
Prologis Euro Prop
ProQR Therapeutics
PROSIEBENSAT.1 MEDIA SE
Prosus
Proximus
Qrf
Qualcomm
Quest For Growth
Rabobank Certificaat
Randstad
Range Beleggen
Recticel
Reed Elsevier
Reesink
Refresco Gerber
Reibel
Relief therapeutics
Renewi
Rente en valuta
Resilux
Retail Estates
RoodMicrotec
Roularta Media
Royal Bank Of Scotland
Royal Dutch Shell
RTL Group
RTL Group
S&P 500
Samas Groep
Sapec
SBM Offshore
Scandinavische (Noorse, Zweedse, Deense, Finse) aandelen
Schuitema
Seagull
Sequana Medical
Shurgard
Siemens Gamesa
Sif Holding
Signify
Simac
Sioen Industries
Sipef
Sligro Food Group
SMA Solar technology
Smartphoto Group
Smit Internationale
Snowworld
SNS Fundcoach Beleggingsfondsen Competitie
SNS Reaal
SNS Small & Midcap Competitie
Sofina
Softimat
Solocal Group
Solvac
Solvay
Sopheon
Spadel
Sparen voor later
Spectra7 Microsystems
Spotify
Spyker N.V.
Stellantis
Stellantis
Stern
Stork
Sucraf A en B
Sunrun
Super de Boer
SVK (Scheerders van Kerchove)
Syensqo
Systeem Trading
Taiwan Semiconductor Manufacturing Company (TSMC)
Technicolor
Tele Atlas
Telegraaf Media
Telenet Groep Holding
Tencent Holdings Ltd
Tesla Motors Inc.
Tessenderlo Group
Tetragon Financial Group
Teva Pharmaceutical Industries
Texaf
Theon International
TherapeuticsMD
Thunderbird Resorts
TIE
Tigenix
Tikkurila
TINC
TITAN CEMENT INTERNATIONAL
TKH Group
TMC
TNT Express
TomTom
Transocean
Trigano
Tubize
Turbo's
Twilio
UCB
Umicore
Unibail-Rodamco
Unifiedpost
Unilever
Unilever
uniQure
Unit 4 Agresso
Univar
Universal Music Group
USG People
Vallourec
Value8
Value8 Cum Pref
Van de Velde
Van Lanschot
Vastned
Vastned Retail Belgium
Vedior
VendexKBB
VEON
Vermogensbeheer
Versatel
VESTAS WIND SYSTEMS
VGP
Via Net.Works
Viohalco
Vivendi
Vivoryon Therapeutics
VNU
VolkerWessels
Volkswagen
Volta Finance
Vonovia
Vopak
Warehouses
Wave Life Sciences Ltd
Wavin
WDP
Wegener
Weibo Corp
Wereldhave
Wereldhave Belgium
Wessanen
What's Cooking
Wolters Kluwer
X-FAB
Xebec
Xeikon
Xior
Yatra Capital Limited
Zalando
Zenitel
Zénobe Gramme
Ziggo
Zilver - Silver World Spot (USD)